Xeraya Capital — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
Liquidia develops and commercializes inhaled and injectable therapies for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechMorrisville, US
Damian deGoa(Executive Officer, Director)inMichael Kaseta(Executive Officer)in
BoardPaul B. Manning(Director)inStephen Bloch(Director)inJoanna Horobin(Director)Raman Singh(Director)
Co-investorsCanaan PartnersNew Enterprise Associates (NEA)PBM Capital
BiotechPhoenix, US
Douglas Grant McFadden, Ph.D.(Director)Steven J. Potts, Ph.D.(President and Chief Executive Officer)Ting Xiao(Director)Jason Rushton(Director)Kanad Das, Ph.D.(Director)Michael G. Wood(Executive Officer)
Co-investorsB Capital GroupBoehringer Ingelheim Venture FundCity Hill VenturesDelos CapitalKorea Investment PartnersLumira Ventures+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.



.jpeg)

